Table 1.
Baseline characteristics of patients <60 and ≥60 years of age in the 3101 and 3102 studies.
| 3101 Study (NHL) | 3102 Study (MM) | |||||||
|---|---|---|---|---|---|---|---|---|
| <60 years | ≥60 years | <60 years | ≥60 years | |||||
| Plerixafor + G-CSF (n = 93) |
Placebo + G-CSF (n = 81) |
Plerixafor + G-CSF (n = 57) |
Placebo + G-CSF (n = 67) |
Plerixafor + G-CSF (n = 79) |
Placebo + G-CSF (n = 78) |
Plerixafor + G-CSF (n = 69) |
Placebo + G-CSF (n = 76) |
|
| Median age at enrollment (range), years |
50.0 (29-59) |
53.0 (22-59) |
65.0 (60-75) |
65.0 (60-75) |
53.0 (28-59) |
54.0 (28-59) |
64.0 (60-75) |
64.5 (60-75) |
| Median time since diagnosis, months |
10.0 | 11.0 | 17.0 | 13.0 | 6.5 | 6.0 | 7.0 | 7.0 |
| Median time since progression/relapse, months (n) |
4.0 (40) | 4.0 (45) | 4.0 | 4.0 | 5.0 (8) | 4.0 (3) | 3.0 | 4.0 |
| Stage of disease at diagnosis, n (%) |
||||||||
| I | 5 (5.4) | 6 (7.4) | 11 (19.3) | 4 (6.0) | 13 (16.5) | 8 (10.3) | 15 (21.7) | 11 (14.5) |
| II | 9 (9.7) | 17 (21.0) | 6 (10.5) | 15 (22.4) | 11 (13.9) | 24 (30.8) | 17 (24.6) | 17 (22.4) |
| III | 23 (24.7) | 28 (34.6) | 6 (10.5) | 16 (23.9) | 54 (68.4) | 42 (53.8) | 37 (53.6) | 47 (61.8) |
| IV | 50 (53.8) | 27 (33.3) | 34 (59.6) | 31 (46.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Missing | 6 (6.5) | 3 (3.7) | 0 (0) | 1 (1.5) | 1 (1.3) | 4 (5.1) | 0 (0) | 1 (1.3) |